SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-13-439209
Filing Date
2013-11-13
Accepted
2013-11-13 06:08:16
Documents
11
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d605284d10q.htm 10-Q 528263
2 EX-31.1 d605284dex311.htm EX-31.1 5605
3 EX-31.2 d605284dex312.htm EX-31.2 5623
4 EX-32.1 d605284dex321.htm EX-32.1 2984
5 EX-32.2 d605284dex322.htm EX-32.2 3000
  Complete submission text file 0001193125-13-439209.txt   3160073

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT fprx-20130930.xml EX-101.INS 412466
7 XBRL TAXONOMY EXTENSION SCHEMA fprx-20130930.xsd EX-101.SCH 34758
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fprx-20130930_cal.xml EX-101.CAL 41144
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fprx-20130930_def.xml EX-101.DEF 89571
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20130930_lab.xml EX-101.LAB 261576
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20130930_pre.xml EX-101.PRE 172939
Mailing Address TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080
Business Address TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS INC (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36070 | Film No.: 131212402
SIC: 2834 Pharmaceutical Preparations